Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.

PURPOSE To characterize the molecular sequelae induced in retinoblastoma (Rb) cells by histone deacetylase inhibitors (HDACIs). Hydroxamic acid-based HDACIs such as vorinostat (suberoylanilide hydroxamic acid) induce the differentiation and apoptosis of transformed cells. Vorinostat has demonstrated significant anticancer activity against hematologic and solid tumors at doses well tolerated by patients and has been approved for the treatment of patients with cutaneous T-cell lymphoma. METHODS The authors evaluated the effects of the HDACIs vorinostat and m-carboxycinnamic acid bis-hydroxamide on the Rb cell lines Y79 and WERI-Rb1 with the use of the MTT assay, BrdU incorporation assay, flow cytometry, immunoblotting, gene-expression profiling, quantitative RT-PCR, and NF-kappaB DNA-binding assay. RESULTS Both HDACIs were effective against both Rb cell lines, inducing growth arrest and apoptosis in vitro. Vorinostat increased p53 expression and activated caspases -8, -9 and -3, whereas caspase inhibition abrogated vorinostat-induced apoptosis. Vorinostat downregulated baseline NF-kappaB activity and potentiated the activity of the DNA-damaging chemotherapeutic doxorubicin. Gene expression profiling and qRT-PCR demonstrated that vorinostat modulated the mRNA levels of genes important for signal transduction, cell cycle, cellular metabolism, stress response, apoptosis, extracellular matrix synthesis, and cell differentiation. Notably, several transcripts involved in the ephrin and Notch signaling pathways were upregulated. CONCLUSIONS HDACIs, such as vorinostat, induce caspase-dependent apoptosis in Rb cells, downregulate baseline NF-kappaB activity, and potentiate the effectiveness of conventional chemotherapy. The finding that vorinostat augments the effectiveness of doxorubicin provides a rationale for future clinical studies looking at the use of vorinostat in combination with conventional chemotherapy in Rb.

[1]  S. Brodie,et al.  Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma , 2009, Documenta Ophthalmologica.

[2]  Herb Chen,et al.  Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. , 2008, Surgery.

[3]  D. Abramson,et al.  Retinoblastoma: what is new in 2007–2008 , 2008, Current opinion in ophthalmology.

[4]  S. Brodie,et al.  A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. , 2008, Ophthalmology.

[5]  Herb Chen,et al.  Valproic acid induces Notch1 signaling in small cell lung cancer cells. , 2008, The Journal of surgical research.

[6]  D. Abramson,et al.  The adverse events of chemotherapy for retinoblastoma: what are they? Do we know? , 2008, Archives of ophthalmology.

[7]  J. O'Brien,et al.  Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma , 2008, Clinical Cancer Research.

[8]  Elena B Pasquale,et al.  Eph-Ephrin Bidirectional Signaling in Physiology and Disease , 2008, Cell.

[9]  E. Batlle,et al.  Eph-ephrin signalling in adult tissues and cancer. , 2008, Current opinion in cell biology.

[10]  Linda Z Sun,et al.  Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma , 2008, Leukemia & lymphoma.

[11]  T. Hadjistilianou,et al.  Does the evidence matter in medicine? The retinoblastoma paradigm , 2007, International journal of cancer.

[12]  J. Lloreta,et al.  EphB–ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells , 2007, Nature Genetics.

[13]  Richard Pazdur,et al.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. , 2007, The oncologist.

[14]  Joseph Negri,et al.  The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. , 2007, Investigative ophthalmology & visual science.

[15]  P. Marks,et al.  Histone Deacetylase Inhibitors: Overview and Perspectives , 2007, Molecular Cancer Research.

[16]  P. Marks,et al.  Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.

[17]  Herb Chen,et al.  Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. , 2007, The oncologist.

[18]  T. Kuzel,et al.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Hadjistilianou,et al.  Retinoblastoma epidemiology: does the evidence matter? , 2007, European journal of cancer.

[20]  P. Marks,et al.  Discovery and development of SAHA as an anticancer agent , 2007, Oncogene.

[21]  Peter Bosma,et al.  Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma. , 2005, Experimental cell research.

[22]  I. Jurisica,et al.  The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells , 2005, Leukemia.

[23]  T. Pawson,et al.  EphB receptor activity suppresses colorectal cancer progression , 2005, Nature.

[24]  L. Schwartz,et al.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Marks,et al.  Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer , 2005, Clinical Cancer Research.

[26]  C. Manetopoulos,et al.  Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells , 2005, British Journal of Cancer.

[27]  Marie Joseph,et al.  Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Schwartz,et al.  Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  N. Munshi,et al.  Molecular sequelae of histone deacetylase inhibition in human malignant B cells. , 2003, Blood.

[30]  N. Mitsiades,et al.  Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability. , 2002, The American journal of pathology.

[31]  S. Bates,et al.  Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[33]  V. Richon,et al.  Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.

[34]  M. Guenther,et al.  Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.

[35]  S. Korsmeyer,et al.  Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c , 2000, Cell Death and Differentiation.

[36]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[37]  R. Vento,et al.  The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. , 1999, Cancer research.

[38]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[39]  M. Madigan,et al.  Vincristine- and cisplatin-induced apoptosis in human retinoblastoma. Potentiation by sodium butyrate. , 1998, European journal of cancer.

[40]  P. Marks,et al.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Dean,et al.  Rb Interacts with Histone Deacetylase to Repress Transcription , 1998, Cell.

[42]  Tony Kouzarides,et al.  Retinoblastoma protein recruits histone deacetylase to repress transcription , 1998, Nature.

[43]  D. Albert,et al.  Effect of butyrate and corticosteroids on retinoblastoma in vitro and in vivo. , 1991, Investigative ophthalmology & visual science.

[44]  G. Chader,et al.  Effects of butyrate, retinol, and retinoic acid on human Y-79 retinoblastoma cells growing in monolayer cultures. , 1984, Journal of the National Cancer Institute.

[45]  R. Reeves,et al.  Sodium butyrate inhibits histone deacetylation in cultured cells , 1978, Cell.

[46]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[48]  Joan W. Miller,et al.  Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing. , 2005, Investigative ophthalmology & visual science.

[49]  P. Marks,et al.  Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. , 2001, Blood cells, molecules & diseases.

[50]  M. Madigan,et al.  Induction of apoptosis by sodium butyrate in the human Y-79 retinoblastoma cell line. , 1995, Oncology research.